Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ursodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 5/20 | 0.89 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.89 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.89 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.89 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.89 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.89 |
| ▸ | CASP7 | P55210 | 3/20 | 0.86 |
| ▸ | TP53 | P04637 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chenodiol SCHEMBL2638869 | 1.00 | GPBAR1 (0.89) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL24124587 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL22079179 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL22108119 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL25337648 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL24199134 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL24061005 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL25397934 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL23517166 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A | |
| Chenodiol SCHEMBL23704676 | 0.94 | GPBAR1 (1.00) | GPBAR1NR1H4TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269639-B1 | Influenza vaccine formulations for intradermal delivery | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-28 | — | — | EP | disclosed |
| US-9138471-B2 | Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2015-09-22 | — | — | US | disclosed |
| US-20140302090-A1 | NOVEL VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-10-09 | — | — | US | disclosed |
| US-8557251-B2 | Non-live trivalent influenza vaccine for one-dose intradermal delivery | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120039933-A1 | METHODS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120029437-A1 | KITS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| EP-1361890-B1 | INFLUENZA VACCINE FORMULATIONS FOR INTRADERMAL DELIVERY | GLAXOSMITHKLINE BIOLOG SA (BE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2281573-A2 | Influenza vaccine formulations for intradermal delivery | GlaxoSmithKline Biologicals s.a. (BE) | 2011-02-09 | — | — | EP | disclosed |
| EP-2269639-A2 | Influenza vaccine formulations for intradermal delivery | GlaxoSmithKline Biologicals s.a. (BE) | 2011-01-05 | — | — | EP | disclosed |
| US-20090155309-A1 | Novel vaccine | SMITHKLINE BEECHAM BIOLOGICALS, S.A. | 2009-06-18 | — | — | US | disclosed |
| EP-1324769-A2 | SPLIT ENVELOPED VIRUS PREPARATION FOR INTRANASAL DELIVERY | GlaxoSmithKline Biologicals S.A. (BE) | 2003-07-09 | — | — | EP | disclosed |
| EP-1322329-A1 | SPLIT ENVELOPED VIRUS PREPARATION | GlaxoSmithKline Biologicals S.A. (BE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002087494-A2 | NOVEL VACCINE | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002067983-A1 | NOVEL VACCINE | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2002-09-06 | — | — | WO | disclosed |
| EP-1214053-A1 | ADJUVANT COMPRISING A POLYOXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT | SMITHKLINE BEECHAM BIOLOGICALS s.a. (BE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214054-A1 | INTRANASAL INFLUENZA VIRUS VACCINE | SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) (BE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002028422-A2 | SPLIT ENVELOPED VIRUS PREPARATION FOR INTRANASAL DELIVERY | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002028426-A1 | SPLIT ENVELOPED VIRUS PREPARATION | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001021152-A1 | ADJUVANT COMPRISING A POLYXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT | SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021151-A1 | INTRANASAL INFLUENZA VIRUS VACCINE | SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155309-A1 | Novel vaccine | TLR7, PDE11A, TLR5 | NR1H4 4538/4885GPBAR1 4017/4885TDP1 4542/4885 |
| US-20140302090-A1 | NOVEL VACCINE | IPO5, IPO4, CD209 | NR1H4 4635/4885GPBAR1 4783/4885TDP1 4311/4885 |
| US-20120039933-A1 | METHODS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE | TIMCC, IDO1, FCGR3B | NR1H4 2630/4885GPBAR1 2838/4885TDP1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.